Indaptus Therapeutics Reports Q2 2026 Financial Results

What Happened

• Indaptus Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release dated August 13, 2026 (furnished as Exhibit 99.1 to the Form 8-K). The press release includes business updates and forward-looking statements.
• The company also reported results from its 2026 annual meeting of stockholders held on August 10, 2026.

Key Details

• Shares outstanding (Record Date June 12, 2026): 113,242,324; shares present or represented at the meeting: 109,556,567 (≈96.75% of outstanding).
• Directors elected (Class II, term to 2029): David Natan (For: 109,029,775; Withheld: 12,547; Broker non-votes: 514,245), Tim Ruan (For: 109,039,888; Withheld: 2,434; Broker non-votes: 514,245), Dr. Johnny Fox Arrowsmith (Yi Zhang) (For: 109,039,709; Withheld: 2,613; Broker non-votes: 514,245).
• Audit firm ratified: Haskell & White LLP approved as independent registered public accounting firm for fiscal year ending Dec 31, 2026 (For: 109,550,863; Against: 3,843; Abstained: 1,861).
• Equity plan approved: Indaptus Therapeutics, Inc. 2026 Equity Incentive Plan approved (For: 109,016,500; Against: 25,093; Abstained: 727; Broker non-votes: 514,247).

Why It Matters

• The furnished press release provides the company's latest quarterly financial results and business outlook, giving investors current visibility into performance for Q2 2026.
• Election of the three Class II directors confirms the board composition through 2029; ratification of the auditor maintains the company’s external financial oversight.
• Approval of the 2026 Equity Incentive Plan authorizes future equity awards, which can affect share-based compensation and potential dilution; investors should watch future disclosures for grant activity and details of the Q2 financials in the press release.